title: [Changes in regional meningeal immunity in local immunomodulating therapy in patients with acute traumatic intracranial hematomas].
abstract: A clinicomorphological study of 660 patients with acute traumatic intracranial hematomas has shown that pneummonia develops in 56% of cases, intracranial complications (purulent meningitis) in 14%.Pyoinflammatory complications were 1.5-1.7 times less common in small-sized hematomas, their total rate and the rate of pneumonias was twice higher in left cerebral hemispheric lesion. On the contrary, intracranial complications were twice more common in right cerebral hemispheric lesion. The structural bases of the regional meningeal immunity system were as follows: the pathways of blood and spinal fluid circulation and dural arachnoidal intercellular fluid; cellular cooperation of the meninx and tissue of the brain; the network of lymph vessels of the dura mater encephali and adventitia of large blood vessels and middle and inferior jugular (regional) lymph nodes. Morphodunctional changes in the local meningeal immunity system in patients with hematomas point to the development of secondary immunodeficiency. Inclusion of regional immunotherapy with T-activin into multimodality treatment decreases the incidence of extra- and intracranial pyoinflammatory complications and mortality.
authors.forename: O V
authors.initials: OV
authors.lastname: Zaĭrat'iants
authors.forename: S V
authors.initials: SV
authors.lastname: Kolobov
authors.forename: V P
authors.initials: VP
authors.lastname: Shevchenko
authors.forename: F A
authors.initials: FA
authors.lastname: Farkhat
authors.forename: S N
authors.initials: SN
authors.lastname: Liubimov
authors.forename: G O
authors.initials: GO
authors.lastname: Zaĭrat'iants
authors.forename: S N
authors.initials: SN
authors.lastname: Mironov
authors.forename: O M
authors.initials: OM
authors.lastname: Serdiuk
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D001921:Brain / Q000098:blood supply / Q000276:immunology* / Q000473:pathology; D005260:Female; D006801:Humans; D007167:Immunotherapy; D020198:Intracranial Hemorrhage, Traumatic / Q000134:cerebrospinal fluid / Q000150:complications / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008297:Male; D008578:Meninges / Q000098:blood supply / Q000276:immunology* / Q000473:pathology; D008581:Meningitis / Q000134:cerebrospinal fluid / Q000209:etiology / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage*; D011014:Pneumonia / Q000134:cerebrospinal fluid / Q000209:etiology / Q000276:immunology / Q000473:pathology / Q000628:therapy; D013949:Thymus Extracts / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin